A scientific or medical reference publication that is distributed should not be…edited or significantly influenced by a drug or device manufacturer or any individuals having a financial relationship with the manufacturer.

I think that knocks the majority of potential reprints off the table from the get-go, and really reduces the possible effect (good or bad) of this more lax guidance. If that statement holds, I don’t see how this new regulation will have much impact at all.